Kenvue fights back against Tylenol safety concerns as its stock tumbles
1. Kenvue shares fell 9.4% amid autism allegations linked to acetaminophen. 2. Stock closed at a 13-month low, signaling heightened investor concern. 3. Kenvue asserts no causal link between acetaminophen and autism based on multiple studies. 4. Kennedy's report expected in September fuels market anxiety around Kenvue. 5. Kenvue's stock has declined 12.8% in 2025, underperforming the S&P 500.